Moderna, Inc. - Special Call Transcript
Good morning, and welcome to Moderna's American Society of Clinical Oncology Review Call. (Operator Instructions) Please be advised that the call is being recorded.
At this time, I'd like to turn the call over to Lavina Talukdar, Head, Investor Relations at Moderna. Please proceed.
Thank you, operator. Good morning, and welcome to Moderna's ASCO 2019 update call. On today's call, we will review interim data from our Phase I personalized cancer vaccine study that was presented at the American Society of Clinical Oncology meeting over the weekend. You can access the press release issued as well as the studies that we'll be reviewing by going to the investors section of our website at www.modernatx.com.
With me on this call is Stéphane Bancel, Chief Executive Officer; Tal Zaks, Chief Medical Officer; and Lorence Kim, Chief Financial Officer.
Before I begin, I would like to remind everyone that this conference call will include
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |